Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech for less than a buck. -- Ignore unavailable to you. Want to Upgrade?

To: RWReeves who wrote (658)	1/9/2001 1:43:48 PM
From: RWReeves	Read Replies (1) \| Respond to of 743

Bloodbath in ALLP today- is it necessary? One of those gotcha's where your control group does anomalously well but your AE profile is not bad in and of itself. Fools need not rush in but maybe pick up a few pieces? I have to say I was wrong about SYBB in a similar case. I thought they should have gone ahead with it (entirely different therapeutic- similar only in circumstances of efficacy but imperfect AE's).I picked them up on speculation they would go back and finish the trials. But they didin't and it ended up a wash. So only opportunity cost for an option-like arrangement. Shame for all those kids. Hey Fido! What's with those CIST shares back in my account? I loved Levinson's H&Q keynote- "Do like we do- abandon those trial failures". Heh heh if we all had gigabucks in the bank and a boatload of pipeline and partners we wouldn't have BTFLTAB would we? The new year starting out right. "We pay cash when your trials crash". Alright you guys quit twisiting the knife on GLIA already. I'm still nibbling below 4 bucks. So there. Anyone else see the ACLA/sCALP settlement? I love stock swaps between mortal enemies. Does the conversion price effectively cap ACLA's stock price? Inquiring minds need answers like this. RWR